Actively Recruiting
Evaluating Activated T Lymphocytes ATL Treatment Safety and Effectiveness in Hepatocellular Carcinoma Patients After Curative Therapy
Led by Lukas Biomedical Inc. · Updated on 2026-09-01
95
Participants Needed
14
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of autologous Activated T Lymphocytes ATL as a preventive immunotherapy in patients with hepatocellular carcinoma HCC who have undergone curative treatment. This Phase II, open-label, single-arm, multicenter study focuses on patients with Stage I, II, or IIIa HCC, reflecting a previous studys patient distribution. The goal is to assess relapse-free survival over 12 months following ATL administration. Eligible patients will receive ten intravenous infusions of ATL at specific weeks 1, 2, 3, 4, 6, 8, 10, 14, 18, and 22. Before treatment, peripheral blood is collected at least 28 days prior to manufacturing the ATL agent. The first three patients receive the ATL doses in a staggered manner to monitor safety. A Data and Safety Monitoring Board will review safety data after 10% of participants complete four ATL infusions to decide on study continuation or adjustments. Participants will be closely monitored through various assessments including blood tests, imaging MRI or CT scans, and evaluations of performance status and quality of life using standardized questionnaires. Safety measures include monitoring adverse events, vital signs, lab values, ECG results, and physical exams over a period of up to 76 weeks. The primary outcome is relapse-free survival at 12 months post-treatment initiation, with additional secondary outcomes assessing overall survival, biomarkers, and functional status changes.
CONDITIONS
Brief Title
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Research Team
E
Eric Tang, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here